Sign In
Buy APVO
$5.02
-0.0200 (-0.397%)
At Close: Jun 03, 2026
Aptevo Therapeutics Provides Pipeline Update
09:00am, Wednesday, 10'th Apr 2024
Breast cancer patient who improved from a progressive disease diagnosis to an over nine-month sustained stable disease diagnosis has now successfully transitioned to a higher dose level, accessing the
Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference
06:00am, Monday, 18'th Mar 2024
SEATTLE, WA / ACCESSWIRE / March 18, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprie
Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update
08:05am, Tuesday, 05'th Mar 2024
Announces 1H24 Plan for Development of Lead Candidate APVO436 for the Treatment of Frontline Acute Myeloid Leukemia, Interim Results Expected Late 2H24 ALG.APV-527 Phase 1 Trial for the Treatment of M
Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan
09:00am, Monday, 04'th Mar 2024
SEATTLE, WA / ACCESSWIRE / March 4, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), today announced that it will conduct a reverse stock split of its outstanding shares of c
Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Update
08:05am, Tuesday, 14'th Nov 2023
The Company's ALG.APV-527 Phase 1 Trial for the Treatment of Multiple Solid Tumors Continues to Progress Planning for APVO436 Phase 2 Trial Initiation in Both Relapsed/Refractory and Frontline AML Ong
Aptevo to Present at Bio-Europe Conference
07:45am, Wednesday, 01'st Nov 2023
SEATTLE, WA / ACCESSWIRE / November 1, 2023 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its propr
Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business Update
08:05am, Thursday, 10'th Aug 2023
Positive Duration of Remission Data Adds to Growing Body of Clinical Evidence Supporting APVO436 for the Treatment of AML APVO436 Poised for Phase 2 Trial Initiation Later in 2H23 Company Completes $5
Aptevo Therapeutics Inc. Announces Closing of Previously Announced $5 Million Public Offering
06:40pm, Friday, 04'th Aug 2023
SEATTLE, WA / ACCESSWIRE / August 4, 2023 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical stage biotechnology company focused on developing novel immuno-oncology thera
Why Is Aptevo Therapeutics (APVO) Stock Down 33% Today?
08:58am, Wednesday, 02'nd Aug 2023
Aptevo Therapeutics (NASDAQ: APVO ) stock is sliding lower on Wednesday after the biotechnology company announced a public share offering. The APVO stock offering has the company selling 8,064,517 sh
Aptevo Therapeutics Inc. Announces Pricing of $5 Million Public Offering
10:15pm, Tuesday, 01'st Aug 2023
SEATTLE, WA / ACCESSWIRE / August 1, 2023 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical stage biotechnology company focused on developing novel immuno-oncology thera
7 Millionaire-Maker Penny Stocks to Buy Before the Window Closes
02:17pm, Sunday, 30'th Jul 2023
Millionaire-maker penny stocks, as you might guess from the title does not represent a universally accessible sector. While these ideas can possibly make you rich, they can just as easily make you poo
The Top 7 Growth Stocks in Biotech
06:57pm, Friday, 03'rd Mar 2023
Biotech stocks almost always have the potential for significant growth over time. Companies in the sector operate in areas including drug development, medical devices, and diagnostics.
Why OpGen Shares Are Trading Higher By 220%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session
05:14pm, Tuesday, 13'th Dec 2022 Benzinga
Gainers
OpGen, Inc. (NASDAQ: OPGN) shares surged 220% to $0.3994 after the company announced topline data from its Unyvero urinary tract infections (UTI) clinical trial.
Netcapital Inc. (NASDAQ: NCPL
Why Quotient Shares Are Trading Lower By More Than 48%; Here Are 37 Stocks Moving Premarket
12:54pm, Tuesday, 13'th Dec 2022 Benzinga
Gainers
Netcapital Inc. (NASDAQ: NCPL) shares rose 91.3% to $2.65 in pre-market trading following Q2 results. Netcapital posted Q2 earnings of $0.04 per share on sales of $1.78 million.
Jiuzi Holding
Dow Surges Over 250 Points; Weber Shares Spike Higher
07:30pm, Monday, 12'th Dec 2022 Benzinga
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining over 250 points on Monday
The Dow traded up 0.80% to 33,745.43 while the NASDAQ rose 0.42% to 11,050.89. The S&P 500 als
